Highlights Mydecine Innovations Group Inc.

Equities

MYCOF

CA62849F2008

Delayed OTC Markets Other stock markets 09:48:02 2024-05-10 EDT			5-day change	1st Jan Change
0.0112 ^USD	+112.04%		0.00%	-24.83%

05-01	Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding	CI
02-23	Mydecine Innovations Closes Partial Debt Settlement	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mydecine Innovations Group Receives Notice of Allowance from USPTO For MYCO-005 Compound	12-18	MT
Mydecine Innovations Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-17	CI
Mydecine Innovations Group Provided Q4 2023 Business Update	23-10-26	MT
Mydecine Innovations Group Brief: Announced Admission to Trading on AQSE Growth Market in London, UK and First Day of Dealings	23-10-10	MT
Mydecine Innovations Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Mydecine Innovations Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Mydecine Innovations Group Inc. Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting Emp Analogues	23-04-24	CI
Mydecine Innovations Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Pangenomic Health Inc. completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).	22-12-08	CI
Mydecine Innovations Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Pangenomic Health Inc. signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.	22-08-31	CI
Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs	22-08-29	CI
Mydecine Innovations Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs	22-07-19	CI
Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation	22-06-17	CI
Mydecine Innovations Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-15	CI
Mydecine Innovations Group Inc. Receives Conditional IRB Approval for Phase 2B Smoking Cessation Study	22-03-24	CI
Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study	22-03-01	CI
Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules	22-02-16	CI
Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada	22-02-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mydecine Innovations Group Inc.

Equities

MYCOF

CA62849F2008

Highlights

Filters